These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1019 related articles for article (PubMed ID: 11314429)

  • 21. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
    Ardern-Jones A; Kenen R; Eeles R
    Eur J Cancer Care (Engl); 2005 Jul; 14(3):272-81. PubMed ID: 15952973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Genetic test and prophylactic treatment in breast cancer families].
    Miyoshi Y; Noguchi S
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families.
    Struewing JP; Lerman C; Kase RG; Giambarresi TR; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):169-73. PubMed ID: 7742725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
    Metcalfe KA; Poll A; Llacuachaqui M; Nanda S; Tulman A; Mian N; Sun P; Narod SA
    Clin Genet; 2010 Nov; 78(5):411-7. PubMed ID: 20653694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
    Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result.
    Dorval M; Gauthier G; Maunsell E; Dugas MJ; Rouleau I; Chiquette J; Plante M; Laframboise R; Gaudet M; Bridge PJ; Simard J
    Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2862-7. PubMed ID: 16365001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.
    van Dijk S; Timmermans DR; Meijers-Heijboer H; Tibben A; van Asperen CJ; Otten W
    J Clin Oncol; 2006 Aug; 24(22):3672-7. PubMed ID: 16877736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors affecting genetic testing and decisions about prophylactic surgery.
    Mahon SM
    Clin J Oncol Nurs; 2001; 5(3):117-20. PubMed ID: 11899370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tumor risk consultation for predisposed women from high risk cancer families].
    Beckmann MW; Niederacher D; Bodden-Heidrich R; Goecke TO; Kuschel B; Achnoula M; Aba F; Schnürch HG; Bender HG
    Praxis (Bern 1994); 1998 Apr; 87(15):511-5. PubMed ID: 9608246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations.
    Esplen MJ; Hunter J; Leszcz M; Warner E; Narod S; Metcalfe K; Glendon G; Butler K; Liede A; Young MA; Kieffer S; DiProspero L; Irwin E; Wong J
    Cancer; 2004 Nov; 101(10):2327-40. PubMed ID: 15478194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
    Balmaña J; Díez O; Campos B; Majewski M; Sanz J; Alonso C; Baiget M; Garber JE
    Breast Cancer Res Treat; 2005 Aug; 92(3):273-7. PubMed ID: 16155798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
    Grann VR; Jacobson JS; Sundararajan V; Albert SM; Troxel AB; Neugut AI
    Cancer J Sci Am; 1999; 5(5):283-92. PubMed ID: 10526669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
    J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA1 and BRCA2 mutations in a South American population.
    Jara L; Ampuero S; Santibáñez E; Seccia L; Rodríguez J; Bustamante M; Martínez V; Catenaccio A; Lay-Son G; Blanco R; Reyes JM
    Cancer Genet Cytogenet; 2006 Apr; 166(1):36-45. PubMed ID: 16616110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects.
    Goelen G; Teugels E; Bonduelle M; Neyns B; De Grève J
    J Med Genet; 1999 Apr; 36(4):304-8. PubMed ID: 10227398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.